sensus healthcare, inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancer and keloids. sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (srt), which is a result of over a decade of dedicated research and development activities. sensus has successfully incorporated the srt therapy into its portfolio of treatment devices: srt-100™ and srt-100 vision™. srt technology effectively and safely treats oncological and non-oncological skin conditions. for more information, visit http://www.sensushealthcare.com.
Company profile
Ticker
SRTS
Exchange
Website
CEO
Joseph Sardano
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Sensus Healthcare, LLC
SEC CIK
SRTS stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
18 Apr 24
10-K
2023 FY
Annual report
15 Mar 24
8-K
Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results
8 Feb 24
8-K
Departure of Directors or Certain Officers
2 Feb 24
8-K
Departure of Directors or Certain Officers
18 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Sensus Healthcare Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Entry into a Material Definitive Agreement
14 Sep 23
S-8
Registration of securities for employees
11 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
Transcripts
SRTS
Earnings call transcript
2023 Q4
8 Feb 24
SRTS
Earnings call transcript
2023 Q3
9 Nov 23
SRTS
Earnings call transcript
2023 Q2
3 Aug 23
SRTS
Earnings call transcript
2023 Q1
2 May 23
SRTS
Earnings call transcript
2022 Q4
9 Feb 23
SRTS
Earnings call transcript
2022 Q3
6 Nov 22
SRTS
Earnings call transcript
2022 Q2
7 Aug 22
SRTS
Earnings call transcript
2022 Q1
8 May 22
SRTS
Earnings call transcript
2021 Q4
11 Feb 22
SRTS
Earnings call transcript
2021 Q3
7 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 20.49 mm | 20.49 mm | 20.49 mm | 20.49 mm | 20.49 mm | 20.49 mm |
Cash burn (monthly) | (no burn) | 1.42 mm | 631.67 k | 129.50 k | (no burn) | 1.24 mm |
Cash used (since last report) | n/a | 9.82 mm | 4.36 mm | 893.33 k | n/a | 8.58 mm |
Cash remaining | n/a | 10.66 mm | 16.13 mm | 19.59 mm | n/a | 11.91 mm |
Runway (months of cash) | n/a | 7.5 | 25.5 | 151.3 | n/a | 9.6 |
Institutional ownership, Q2 2023
20.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 47 |
Opened positions | 3 |
Closed positions | 20 |
Increased positions | 18 |
Reduced positions | 18 |
13F shares | Current |
---|---|
Total value | 7.32 bn |
Total shares | 3.37 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 779.05 k | $2.45 bn |
Renaissance Technologies | 367.93 k | $1.16 mm |
Acadian Asset Management | 348.96 k | $1.10 mm |
Nantahala Capital Management | 185.05 k | $582.90 mm |
BK Bank Of New York Mellon | 161.18 k | $507.70 mm |
Gsa Capital Partners | 156.74 k | $494.00 k |
Geode Capital Management | 132.60 k | $417.69 mm |
Perritt Capital Management | 100.59 k | $316.85 mm |
D. E. Shaw & Co. | 92.78 k | $292.25 mm |
Cahill Wealth Management | 73.86 k | $232.66 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Jan 24 | Sardano Michael | Common Stock | Grant | Acquire A | No | No | 0 | 20,000 | 0.00 | 78,774 |
19 Dec 23 | Magdalena Martinez | Common Stock | Payment of exercise | Dispose F | No | No | 2.66 | 741 | 1.97 k | 9,759 |
14 Sep 23 | Sardano Joseph C | Common Stock | Buy | Acquire P | No | No | 2.8773 | 10,000 | 28.77 k | 1,175,293 |
28 Aug 23 | Sardano Michael | Common Stock | Buy | Acquire P | No | No | 2.99 | 1,000 | 2.99 k | 58,774 |
8 Aug 23 | Sardano Joseph C | Common Stock | Buy | Acquire P | No | No | 3.8574 | 10,000 | 38.57 k | 1,165,293 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
8 Feb 24
Sensus Healthcare Q4 2023 GAAP EPS $0.26 Beats $0.12 Estimate, Sales $12.57M Beat $11.06M Estimate
8 Feb 24
Recap: Sensus Healthcare Q4 Earnings
8 Feb 24
Earnings Scheduled For February 8, 2024
8 Feb 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
7 Feb 24
Press releases
Sensus Healthcare Issues Reminder That its First Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, May 9, 2024
25 Apr 24
Thinking about buying stock in Healthequity, Pacira Biosciences, Interpublic Group of Companies, SIGA Technologies, or Sensus Healthcare?
21 Mar 24
SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555
7 Mar 24
Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results
8 Feb 24